Niacin extended-release therapy in phase III clinical trials is associated with relatively low rates of drug discontinuation due to flushing and treatment-related adverse events: a pooled analysis (Q84210080)
Jump to navigation
Jump to search
scientific article published on 01 June 2011
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Niacin extended-release therapy in phase III clinical trials is associated with relatively low rates of drug discontinuation due to flushing and treatment-related adverse events: a pooled analysis |
scientific article published on 01 June 2011 |
Statements
Niacin extended-release therapy in phase III clinical trials is associated with relatively low rates of drug discontinuation due to flushing and treatment-related adverse events: a pooled analysis (English)
Eliot A Brinton
Moti L Kashyap
Anthony N Vo
Roopal B Thakkar
Ping Jiang